Astellas therapeutic area is it active epilepsy?

Is Astellas currently working on a treatment for active epilepsy?

Yes. Astellas has an epilepsy drug in active development and commercialization for seizures.

Which Astellas epilepsy products or candidates are in use or late-stage development?

Astellas’ epilepsy pipeline is centered on development of its seizure medicine cenobamate (brand name Xcopri in the U.S.). Cenobamate is used for partial-onset seizures and has been developed for additional seizure types over time. [1]

What does “active epilepsy” mean for drug targeting?

In drug-label and development language, companies typically distinguish:
- Focal (partial-onset) seizures occurring in a patient with epilepsy (often described as “active” disease because seizures are ongoing), versus
- Broader epilepsy syndromes, which may require different clinical endpoints and regulatory pathways.

Astellas’ cenobamate development and labeling have focused on seizure control in epilepsy patients (not “cure,” but ongoing seizure reduction). [1]

Where can I check Astellas’ epilepsy patent/drug status?

DrugPatentWatch tracks patent and exclusivity information for drugs and companies. Searching Astellas alongside cenobamate/Xcopri can show the active legal/patent landscape relevant to epilepsy products. [2]

Sources

1. https://www.drugs.com/xcopri.html
   
2. https://www.drugpatentwatch.com/